Serotonin Syndrome & Neuroleptic Malignant Syndrome

Overview & definition

The drug-induced hyperthermic syndromes — the serotonin syndrome (the excess serotonin), the neuroleptic malignant syndrome (the NMS) (the dopamine antagonism), and the malignant hyperthermia (the MH) (the volatile + the suxamethonium) — are the distinct, the dangerous, the potentially-lethal entities with the overlapping features (the hyperthermia, the rigidity, the altered mental state) and the different triggers and the different treatments. The accurate, the rapid distinction is the essential. The anticholinergic syndrome is the fourth member of the differential — the dry, the hot, the flushed, the mydriatic, the delirious — distinguished by the peripheral muscarinic blockade and treated by the physostigmine.[1][1][4]

The Fellowship candidate must hold four facts simultaneously: (1) the onset is the discriminator — the minutes for the MH, the hours for the serotonin, the days for the NMS; (2) the neuromuscular sign is the discriminator — the clonus and the hyperreflexia for the serotonin, the lead-pipe rigidity and the bradyreflexia for the NMS, the masseter rigidity for the MH, the dry skin and the mydriasis for the anticholinergic; (3) the antipyretics are useless in all four — the heat is the muscle-generated, not the hypothalamic; (4) the specific antidote differs — the cyproheptadine for the serotonin, the dantrolene and the bromocriptine for the NMS, the dantrolene for the MH, the physostigmine for the anticholinergic.[1][4][9]

The pathophysiology — the receptor pharmacology

The four syndromes share the hyperthermia and the altered mental state but diverge at the receptor. The understanding of the receptor is the understanding of the trigger and the antidote. [1]

The serotonin syndrome is the central serotonergic excess at the 5-HT2A and the 5-HT1A receptors in the brainstem and the spinal cord. The serotonin is the product of the dietary tryptophan, the stored in the presynaptic vesicle by the vesicular monoamine transporter, the released into the synapse, the action terminated by the reuptake (the SERT transporter) and the degradation (the monoamine oxidase). The serotonergic drugs act at every step: the SSRIs and the SNRIs block the reuptake; the MAOIs block the degradation; the tramadol and the pethidine and the fentanyl displace the serotonin and the block the reuptake; the linezolid and the methylene blue are the reversible MAOIs; the MDMA forces the vesicular release. The combination of two drugs acting at the different steps is the lethal — the MAOI (the no degradation) plus the SSRI/tramadol (the no reuptake) produces the unchecked synaptic serotonin and the severe toxicity.[4][7][12]

The NMS is the central dopamine antagonism at the D2 receptors in the hypothalamus and the basal ganglia. The dopamine is the endogenous thermoregulator — the dopamine pathway from the hypothalamus to the peripheral vasculature mediates the heat dissipation, and the dopamine in the basal ganglia modulates the muscle tone. The D2 blockade (the antipsychotic, the antiemetic) removes both the heat dissipation and the muscle-tone modulation — the rigidity and the hyperthermia result. The dopamine-agonist withdrawal (the abrupt cessation of the levodopa or the amantadine in the Parkinson's disease) produces the identical picture by the same mechanism — the empty receptor rather than the blocked receptor.[3][9]

The malignant hyperthermia is the ryanodine receptor (the RyR1) defect in the skeletal muscle sarcoplasmic reticulum. The volatile anaesthetics and the suxamethonium open the defective RyR1 channel — the uncontrolled calcium release from the sarcoplasmic reticulum into the myoplasm, the sustained actin-myosin cross-bridge cycling, the ATP consumption, the heat production, the rigidity, the hyperkalaemia (the leak from the damaged muscle), the acidosis. The calcium is the unable to be re-sequestered — the cycle is the self-sustaining until the dantrolene (the RyR1 blocker) is given. The genetic basis is the autosomal dominant mutation in the RYR1 gene (the 70 to 80 per cent of the cases) or the CACNA1S gene (the 1 per cent).[1][11]

The anticholinergic syndrome is the muscarinic acetylcholine receptor blockade — the central (the delirium, the agitation) and the peripheral (the dry, the dilated, the flushed, the hot, the blind). The mnemonic — the dry as a bone, the red as a beet, the hot as a hare, the blind as a bat, the mad as a hatter — captures the peripheral antimuscarinic effects and the central delirium.[15]

The serotonin syndrome

The serotonin syndrome is the excess of the central serotonin, the produced by the serotonergic agents (the SSRIs, the SNRIs, the MAOIs, the tramadol, the pethidine, the fentanyl, the linezolid, the methylene blue, the MDMA, the triptans, the St John's wort) — the classically the combination (the MAOI + the SSRI/tramadol is the lethal). The onset is the rapid (the hours) after a dose increase or a new agent.[1][2]

The triad:[1]

• The neuromuscular hyperactivity — the clonus (the inducible and the spontaneous, the ocular — the hallmark), the hyperreflexia (the lower-limbs especially), the rigidity (the more the severe, the lower-body), the tremor, the myoclonus.
• The autonomic instability — the hyperthermia, the tachycardia, the hypertension, the mydriasis, the diaphoresis, the diarrhoea, the flushing.
• The altered mental state — the agitation, the confusion, the restlessness.

The clonus is the most specific sign — the inducible (the ankle or the patella) at the milder end, the spontaneous and the ocular (the horizontal) at the severe end. The ocular clonus is the virtually pathognomonic for the serotonergic aetiology. The hyperreflexia is the lower-limb and the exaggerated — the contrast with the bradyreflexia of the NMS is the key discriminator at the bedside. The Babinski may be present (the upper motor neuron).[4][5]

The Hunter criteria (the highly-sensitive-and-specific, the 84 per cent sensitive and the 97 per cent specific): the spontaneous clonus, OR the inducible clonus + the agitation + the diaphoresis, OR the ocular clonus + the agitation + the diaphoresis, OR the tremor + the hyperreflexia, in the context of the serotonergic agent.[5]

The Hunter criteria replaced the older Sternbach criteria, which required the presence in the serotonergic agent and (a) mental status change with (b) two of myoclonus, hyperreflexia, diaphoresis, shivering, tremor, diarrhoea, incoordination, or fever — but the Sternbach criteria missed the milder cases and over-diagnosed the febrile delirium. The Hunter criteria, built on the prospectively-observed Hunter Area Toxicology Service cohort, are the more accurate and the current standard.[4][5]

The neuroleptic malignant syndrome (the NMS)

The NMS is the dopamine antagonism — the antipsychotics (the typical — the haloperidol; the atypical — the olanzapine, the risperidone, the clozapine), the antiemetics (the metoclopramide, the prochlorperazine), and the withdrawal of the dopamine agonist in the Parkinson's disease (the levodopa, the amantadine abruptly stopped). The onset is the slow (the 1 to 3 days).[3][1]

The tetrad:[3]

• The hyperthermia (the over the 38.5 degrees C, the frequently the over 40).
• The lead-pipe rigidity (the extrapyramidal, the generalized; the bradyreflexia — the contrast with the hyperreflexia of the serotonin syndrome); the cogwheeling may be present.
• The autonomic instability (the tachycardia, the labile blood pressure, the diaphoresis, the sialorrhoea — the especially with the clozapine).
• The altered mental state (the stupor, the mutism, the agitation, the coma).

The associated: the elevated creatine kinase (the rhabdomyolysis — the typically the over 1000, the often the over 10,000 units per litre), the transaminitis, the leukocytosis (the typically the 10,000 to 20,000), the renal impairment (the rhabdomyolysis-induced), the hypocalcaemia, the low serum iron (the characteristic but the not the diagnostic).[1][9]

The DSM-5 diagnostic criteria (the five): the muscle rigidity and the elevated temperature (the over 38.5 with no other cause) PLUS at least two of: the diaphoresis, the sialorrhoea, the incontinence, the altered consciousness, the mutism, the tachycardia, the labile or the elevated blood pressure, the leukocytosis, the elevated CK. The DSM-5 criteria are the more specific but the less sensitive than the clinical judgement — the NMS remains the clinical diagnosis.[9]

The incidence — the 0.02 to 0.3 per cent of the patients on the antipsychotics. The mortality — the 5 to 20 per cent (the down from the 25 per cent in the era before the recognition and the dantrolene). The predictors of the mortality (the Guinart pooled analysis) — the higher CK, the higher temperature, the older age, the renal failure, the cognitive impairment, the catatonic features. The NMS with the acute renal failure from the rhabdomyolysis carries the 50 per cent mortality.[9][13]

The malignant hyperthermia (the MH)

The MH is the ryanodine-receptor mutation (the calcium-handling) triggered by the volatile anaesthetics (the halothane, the sevoflurane, the isoflurane, the desflurane) and the suxamethonium — the massive intracellular calcium release, the sustained muscle contraction, the rigidity (the masseter especially — the "the jaw of steel"), the rapid hyperthermia, the hypercarbia, the acidosis, the hyperkalaemia. The onset is the in-the-theatre, the rapid after the trigger (the minutes, the within the first hour of the anaesthesia, the occasionally the delayed to the several hours).[1][11]

The clinical grading scale (the Larach) is the post-hoc research tool — the not the for the acute diagnosis. The acute diagnosis is the clinical: the unexplained hypercarbia (the rising end-tidal CO2 with the unchanged ventilation, the earliest sign), the tachycardia out of proportion, the masseter rigidity (the 50 per cent of the paediatric cases with the suxamethonium), the rapid temperature rise, the hyperkalaemia, the acidosis, the sinus tachycardia then the ventricular arrhythmia. The coffee-coloured urine (the myoglobinuria) is the late sign.[11]

The MH is the inherited (the autosomal dominant) but the sporadic in the 50 per cent (the new mutation or the unrecognised family history). The first presentation may be the third or the fourth anaesthetic — the prior uneventful anaesthetics do NOT exclude the susceptibility. The diagnosis is the in vitro contracture test (the IVCT) — the muscle biopsy (the vastus lateralis) and the exposure to the halothane and the caffeine; the gold standard for the confirmation and the family screening. The genetic testing (the RYR1 and the CACNA1S) is the increasingly used but the lower sensitivity than the IVCT.[1][11]

The anticholinergic syndrome — the fourth member

The anticholinergic syndrome is the muscarinic acetylcholine receptor blockade — the central and the peripheral — produced by the antihistamines (the diphenhydramine, the promethazine), the antispasmodics, the tricyclics (the anticholinergic plus the sodium-channel), the atropine, the hyoscine, the plant toxins (the deadly nightshade — the Atropa belladonna, the thornapple — the Datura stramonium), and the parkinsonian medications (the benztropine, the procyclidine).[15]

The clinical: the dry as a bone, the red as a beet, the hot as a hare, the blind as a bat, the mad as a hatter. The dry — the dry skin and the dry mucosae, the absent sweating, the urinary retention, the ileus. The red — the flushed face. The hot — the hyperthermia. The blind — the cycloplegia and the mydriasis (the loss of the accommodation, the blurred vision). The mad — the central delirium, the agitation, the hallucination (the visual and the auditory), the picking and the plucking (the characteristic movement), the seizures in the severe. The tachycardia is the universal.[15]

The discrimination from the serotonin syndrome — the serotonin syndrome has the clonus, the hyperreflexia, the diaphoresis (the WET skin), the mydriasis with the bowel sounds present; the anticholinergic has the dry skin, the absent bowel sounds, the urinary retention, the hyperreflexia absent. The skin moisture is the single best discriminator at the bedside.[4][15]

The physostigmine (the acetylcholinesterase inhibitor, the crosses the blood-brain barrier) is the specific antidote — the 1 to 2 mg IV in the adult, the slow (the 5 minutes), the onset in the minutes. The use is the controversial — the bradycardia, the bronchospasm, the seizures, the asystole are the reported; the contraindicated in the tricyclic with the QRS widening (the ventricular arrhythmia). The benzodiazepine is the safe alternative for the agitation.[15]

The triggering agents — the comprehensive list

The Fellowship candidate must know the full list — the trigger is the diagnostic, the trigger is the preventable. [1]

The comparison

[1]

Investigations

The diagnosis is the clinical — the no specific confirmatory test. The investigations are the for the severity grading, the complication detection, and the differential exclusion.[1][9]

The laboratory: the creatine kinase (the rhabdomyolysis — the serial, the every 6 to 12 hours), the renal function and the urine output (the AKI from the myoglobin), the liver function (the transaminitis), the full blood count (the leukocytosis in the NMS), the coagulation (the DIC), the electrolytes (the hyperkalaemia in the MH, the hypocalcaemia in the NMS), the serum iron (the low in the NMS — the characteristic), the lactate (the tissue hypoperfusion and the muscle injury), the troponin (the demand ischaemia and the direct injury), the creatinine (the AKI), the arterial or the venous blood gas (the acidosis, the hypercarbia in the MH, the hypoxia in the severe).[1]

The urine — the myoglobin (the red-brown, the positive dipstick for the blood without the red cells, the "the tea-coloured urine"). The toxicology screen — the confirmation of the serotonergic or the antipsychotic exposure (the not the immediate, the for the documentation and the medico-legal). The CT brain — the exclude the structural cause (the intracranial haemorrhage, the meningitis, the encephalitis) in the altered-mental-state patient. The lumbar puncture — the exclude the meningitis and the encephalitis when the fever and the altered mental state coexist. The ECG — the arrhythmia, the QTc prolongation (the antipsychotic), the QRS widening (the TCA).[1][1]

The invasive monitoring in the severe — the arterial line (the beat-to-beat, the labile blood pressure), the central venous line (the inotrope and the vasopressor), the urinary catheter (the urine output, the core temperature), the continuous core temperature (the oesophageal, the bladder, the rectal). The continuous EEG if the seizure suspected or the paralysed patient for the non-convulsive status.[1]

Treatment

The serotonin syndrome.[1][2]

1. Stop the serotonergic agent — the first and the essential.
2. The benzodiazepine (the diazepam, the lorazepam) — the sedation, the muscle relaxation, the reduces the heat generation and the injury. The core therapy. The titrate to the calm (the not the apnoea).
3. The cyproheptadine (the 5-HT2A antagonist) — the specific antidote (the oral/NG; the 12 mg loading, then the 2 mg every 2 h to the 32 mg/day; the maintenance the 8 mg every 8 h for the 2 to 4 weeks). The onset in the hours. The no parenteral formulation — the limitation in the intubated patient (the via the NG).
4. The active cooling (the ice, the blankets, the cold IV fluids, the evaporative, the gastric and the bladder lavage, the intravascular catheter in the severe) — the hyperthermia is the MUSCLE-generated (the not the central fever) — the antipyretics (the paracetamol, the NSAID) are the INEFFECTIVE.
5. The severe — the intubation, the non-depolarising paralysis (the vecuronium, the rocuronium — the AVOID the suxamethonium: the rhabdomyolysis and the hyperkalaemia), the deep sedation (the propofol infusion), the consider the early haemofiltration (the no strong evidence but the used in the refractory).

The NMS.[3][1]

1. Stop the antipsychotic (or the restore the dopamine agonist in the withdrawal). The depot formulation — the longer the risk (the weeks for the decanoate).
2. The supportive — the cooling, the benzodiazepine, the fluids (the rhabdomyolysis — the urine output the 1 to 2 mL/kg/h, the target the alkalinisation of the urine), the renal support (the renal replacement therapy for the AKI), the thromboprophylaxis (the immobility), the pressure-area care.
3. The dantrolene (the 1 to 2.5 mg/kg IV, the repeat to the 10 mg/kg, then the infusion) — the ryanodine-receptor, the reduces the muscle rigidity and the heat. The no strong evidence for the mortality reduction but the clinically effective; the consider in the severe hyperthermia and the rigidity.
4. The bromocriptine (the 2.5 to 5 mg oral/NG, the up to the 45 mg/day in the divided doses) or the amantadine (the 100 mg twice daily) — the dopamine agonists. The onset in the 1 to 2 days. The caution in the hypotension and the psychosis. The continue for the 1 to 2 weeks after the resolution; the abrupt cessation causes the relapse.
5. The renal (the AKI from the rhabdomyolysis), the CK monitoring (the serial, the trend the fall), the ECG (the QTc).

The malignant hyperthermia.[1]

1. Stop the trigger (the volatile off, the switch to the TIVA — the propofol; the flush the circuit with the 100 per cent oxygen at the high flow, the change the circuit and the soda lime if the time allows).
2. The dantrolene (the 2.5 mg/kg IV, the repeat every 5 to 10 minutes to the 10 mg/kg, then the infusion of the 0.25 mg/kg/h for the 24 to 48 hours) — the specific. The onset in the minutes. The new formulation (the Ryanodex) reconstitutes in the seconds; the older (the Dantrium) in the minutes and the multiple vials (the 36 vials for the 70-kg adult at the 10 mg/kg).
3. The cooling, the treat the hyperkalaemia (the insulin-dextrose, the calcium chloride 10 mmol, the salbutamol, the bicarbonate), the acidosis (the bicarbonate, the hyperventilation), the arrhythmia (the lidocaine, the amiodarone — the avoid the calcium-channel blockers with the dantrolene: the severe hyperkalaemia and the cardiovascular collapse).
4. The monitoring for the 48 to 72 hours — the recurrence in the 25 per cent (the recrudescence); the dantrolene infusion continued.
5. The referral for the family screening — the IVCT or the genetic testing; the MedicAlert bracelet; the safe-anaesthesia plan for the future.

The anticholinergic syndrome.[15]

1. Stop the anticholinergic agent.
2. The benzodiazepine (the diazepam, the lorazepam, the midazolam) for the agitation — the safe, the first-line. The AVOID the antipsychotic (the haloperidol, the olanzapine) — the additional anticholinergic and the QTc; the chlorpromazine and the promethazine are the explicitly anticholinergic.
3. The physostigmine (the 1 to 2 mg IV slow over the 5 minutes, the repeat in the 30 minutes to the 2 hours) — the specific antidote. The reserved for the severe delirium with the tachycardia and the agitation resistant to the benzodiazepine; the CONTRAINDICATED in the TCA overdose (the QRS widening — the ventricular arrhythmia and the asystole), the asthma, the intestinal obstruction, the bladder obstruction. The atropine at the bedside for the bradycardia.
4. The supportive — the cooling, the fluids, the cardiac monitoring (the tachyarrhythmia, the QRS), the catheterisation (the urinary retention), the eye care (the corneal abrasion from the dry and the loss of the blink).

[1]

Complications

The complications are the common and the lethal in the untreated or the delayed. The Fellowship candidate must anticipate and the prevent.[1][3][11]

The rhabdomyolysis is the near-universal in the severe NMS and the MH, the common in the severe serotonin syndrome. The CK the over 5000, the myoglobinuria, the acute kidney injury (the pigment nephropathy), the compartment syndrome (the less common but the catastrophic). The treatment — the aggressive fluid, the alkalinisation of the urine, the mannitol in the selected, the renal replacement therapy for the established AKI.[1]

The acute kidney injury — the pigment nephropathy from the myoglobin (the direct tubular toxicity plus the cast formation plus the renal vasoconstriction), the volume depletion, the hypotension. The prevention — the early and the aggressive fluid, the urine output the 1 to 2 mL/kg/h, the target the urine pH over 6.5. The established AKI — the renal replacement therapy.[1]

The disseminated intravascular coagulation — the tissue-factor release from the damaged muscle and the endothelium; the thrombosis and the bleeding. The treatment — the underlying cause, the factor replacement per the viscoelastic or the laboratory, the heparin in the thrombotic phase.[1]

The seizures — the hyperthermia, the electrolyte disturbance (the hyponatraemia, the hypocalcaemia), the direct drug toxicity. The benzodiazepine first-line; the levetiracetam or the phenytoin for the refractory.[1]

The hepatic failure — the direct injury (the transaminitis), the heat stroke picture (the centrilobular necrosis), the drug-induced (the valproate, the statin). The supportive; the N-acetylcysteine if the paracetamol co-ingestion suspected.[1]

The cardiac arrest — the arrhythmia (the hyperkalaemia, the QTc, the QRS), the profound hypotension, the refractory hyperthermia. The periarrest — the immediate dantrolene in the MH, the aggressive cooling, the correction of the potassium and the acidosis.[1]

The aspiration pneumonia — the reduced consciousness, the ileus in the NMS and the anticholinergic. The prevention — the intubation for the GCS under 8, the NG tube on the free drainage, the head-up position.[1]

The deep vein thrombosis and the pulmonary embolism — the immobility, the rigidity, the DIC. The thromboprophylaxis (the enoxaparin 40 mg daily unless the bleeding; the mechanical if the contraindicated).[1]

Prognosis

The mild-to-moderate serotonin syndrome resolves over the 24 to 72 hours with the supportive care and the cyproheptadine. The NMS resolves over the 1 to 2 weeks (the longer than the serotonin syndrome — the drug clearance, the depot the weeks). The mortality is the low with the early recognition and the treatment; the high (the 10 to 20 per cent) in the untreated severe; the 50 per cent in the NMS with the acute renal failure. The MH is the lethal (the 70 per cent) without the dantrolene; the low (the under 5 per cent) with the early dantrolene. The anticholinergic syndrome is the rarely fatal in the adult; the more dangerous in the elderly and the child.[1][3][1][13]

The sequelae of the NMS — the residual cognitive impairment, the parkinsonism (the especially if the dopamine agonist withdrawn), the muscle wasting, the contractures. The sequelae of the MH — the muscle pain, the weakness for the weeks, the renal recovery, the anxiety for the future anaesthetic. The recurrence of the NMS on the antipsychotic re-challenge — the 30 per cent; the wait 2 weeks, the lower-potency, the cross-class, the low dose, the slow titration. The recurrence of the MH — the 25 per cent recrudescence within the 24 to 48 hours; the lifelong avoidance of the volatiles and the suxamethonium; the family screening.[9][11]

[1] [1]

Clinical pearls

Trial cards

[1]

Red flags

Special populations

The elderly — the higher-risk for the NMS (the increased D2-receptor sensitivity, the polypharmacy, the dehydration, the cognitive impairment) and the anticholinergic (the anticholinergic burden of the polypharmacy, the reduced cholinergic reserve). The lower threshold for the benzodiazepine, the cautious physostigmine (the bradycardia), the aggressive hydration.[9][15]

The paediatric — the masseter rigidity after the suxamethonium is the more common (the 50 per cent in the children with the strabismus surgery, the less in the adults). The MH presents the earlier (the first anaesthetic). The dantrolene dose the weight-based (the 2.5 mg/kg). The anticholinergic from the topical mydriatic in the infant (the cyclopentolate, the tropicamide) — the systemic absorption; the diazepam and the cooling.[11]

The pregnant — the serotonin syndrome treated the same (the benzodiazepine, the cyproheptadine — the no strong teratogenicity data, the used in the severe). The NMS the same (the dantrolene — the no strong teratogenicity, the used). The physostigmine the avoided in the pregnancy (the limited data). The delivery the for the obstetric indication, the not the toxicological.[2]

The Parkinson patient — the NMS from the dopamine-agonist withdrawal is the common and the overlooked. The restore the levodopa or the dopamine agonist is the first (the not the bromocriptine alone — the patient is the already on the dopamine agonist). The antipsychotic the avoided in the Parkinson patient; the pimavanserin (the 5-HT2A inverse agonist, the not the D2 blocker) or the quetiapine or the clozapine (the lower D2 affinity) the preferred if the antipsychotic is the necessary.[3][9]

The renal failure — the dantrolene (the hepatic metabolism, the no adjustment) and the bromocriptine (the hepatic, the no adjustment) are the safe. The cyproheptadine (the hepatic, the no adjustment). The physostigmine (the hepatic and the renal, the cautious). The volume management the challenging — the fluid for the rhabdomyolysis balanced against the oliguria; the early renal replacement therapy.[1]

Drug doses — the bedside reference

[1]

References

1. [1]Ahmad SR, et al. Serotonin syndrome-A focused review Basic Clin Pharmacol Toxicol, 2023.PMID 37309284
2. [2]McCarthy R, et al. Management of serotonin syndrome (toxicity) Br J Clin Pharmacol, 2025.PMID 38926083
3. [3]Stübner S, et al. Neuroleptic Malignant Syndrome Ann Pharmacother, 2016.PMID 27423483
4. [4]Boyer EW, Shannon M The serotonin syndrome N Engl J Med, 2005.PMID 15784664
5. [5]Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity QJM, 2003.PMID 12925718
6. [6]Graudins A, Stearman A, Chan B Treatment of the serotonin syndrome with cyproheptadine J Emerg Med, 1998.PMID 9696181
7. [7]Graudins A, Dawson AH, Whyte IM Serotonin syndrome resulting from drug interactions Med J Aust, 1998.PMID 9861909
8. [8]Birmes P, Coppin D, Schmitt L, Lauque D Serotonin syndrome: a brief review CMAJ, 2003.PMID 12771076
9. [9]Strawn JR, Keck PE, Caroff SN Neuroleptic malignant syndrome Am J Psychiatry, 2007.PMID 17541044
10. [10]Rosenberg MR, Green M Neuroleptic malignant syndrome. Review of response to therapy Arch Intern Med, 1989.PMID 2673115
11. [11]Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006 Anesth Analg, 2010.PMID 20081135
12. [12]Gillman PK CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity J Psychopharmacol, 2011.PMID 20142303
13. [13]Guinart D, Misawa F, Rubio JM, Pereira J, Correll CU A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome Acta Psychiatr Scand, 2021.PMID 34358327
14. [14]Isbister GK Selective Serotonin Reuptake Inhibitor Toxicity 2026.PMID 30521236
15. [15]Culbreath K, et al. Diphenhydramine Overdose: A Case Report and Topic Review of Prehospital Diagnosis and Treatment Cureus, 2024.PMID 39493145